MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from equity
offerings
$258,858K
Proceeds from credit
facility
$42,000K
Proceeds from exercise of
2022 usd financing...
$3,767K
Proceeds from exercise of
options
$625K
Proceeds from issuance of
common shares under...
$412K
Net cash provided by
financing activities
$267,269K
Canceled cashflow
$38,393K
Net
increase/(decrease) in cash and cash...
-$15,904K
Canceled cashflow
$267,269K
Maturity of investments
$116,750K
Change in fair value of
2022 usd financing...
$22,831K
Stock-based compensation
$20,096K
Accrued expenses
$5,958K
Accounts payable
$3,337K
Change in fair value on
directors' deferred share...
-$1,460K
Other non-cash
adjustments
$230K
Prepaid and other
current assets
-$152K
Other noncurrent
assets
-$30K
Repayment of credit
facility
$22,000K
Payment of equity
offering costs
$15,946K
Payment of credit
facility issuance costs
$447K
Net cash used in
investing activities
-$151,606K
Canceled cashflow
$116,750K
Net cash used in
operating activities
-$131,560K
Effect of exchange rate
changes on cash
-$7K
Canceled cashflow
$54,094K
Purchases of investments
$268,356K
Net loss
-$183,793K
Accretion of discounts and
premiums on investments,...
$1,821K
Other liabilities,
long-term
$40K
Loss from operations
-$166,309K
Total other expense,
net
-$17,484K
Total
$117,665K
Total
$48,644K
Back
Back
Cash Flow
source: myfinsight.com
Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics, Inc. (DFTX)